These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

281 related articles for article (PubMed ID: 16603352)

  • 1. Design and structure-activity relationship of 3-benzimidazol-2-yl-1H-indazoles as inhibitors of receptor tyrosine kinases.
    McBride CM; Renhowe PA; Heise C; Jansen JM; Lapointe G; Ma S; Piñeda R; Vora J; Wiesmann M; Shafer CM
    Bioorg Med Chem Lett; 2006 Jul; 16(13):3595-9. PubMed ID: 16603352
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 3-Benzimidazol-2-yl-1H-indazoles as potent c-ABL inhibitors.
    McBride CM; Renhowe PA; Gesner TG; Jansen JM; Lin J; Ma S; Zhou Y; Shafer CM
    Bioorg Med Chem Lett; 2006 Jul; 16(14):3789-92. PubMed ID: 16678414
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Design and synthesis of orally bioavailable benzimidazoles as Raf kinase inhibitors.
    Ramurthy S; Subramanian S; Aikawa M; Amiri P; Costales A; Dove J; Fong S; Jansen JM; Levine B; Ma S; McBride CM; Michaelian J; Pick T; Poon DJ; Girish S; Shafer CM; Stuart D; Sung L; Renhowe PA
    J Med Chem; 2008 Nov; 51(22):7049-52. PubMed ID: 18942827
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Design and structure-activity relationship of heterocyclic analogs of 4-amino-3-benzimidazol-2-ylhydroquinolin-2-ones as inhibitors of receptor tyrosine kinases.
    Frazier K; Jazan E; McBride CM; Pecchi S; Renhowe PA; Shafer CM; Taylor C; Bussiere D; He MM; Jansen JM; Lapointe G; Ma S; Vora J; Wiesmann M
    Bioorg Med Chem Lett; 2006 Apr; 16(8):2247-51. PubMed ID: 16446087
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Structure-based design of novel 2-amino-6-phenyl-pyrimido[5',4':5,6]pyrimido[1,2-a]benzimidazol-5(6H)-ones as potent and orally active inhibitors of lymphocyte specific kinase (Lck): synthesis, SAR, and in vivo anti-inflammatory activity.
    Martin MW; Newcomb J; Nunes JJ; Boucher C; Chai L; Epstein LF; Faust T; Flores S; Gallant P; Gore A; Gu Y; Hsieh F; Huang X; Kim JL; Middleton S; Morgenstern K; Oliveira-dos-Santos A; Patel VF; Powers D; Rose P; Tudor Y; Turci SM; Welcher AA; Zack D; Zhao H; Zhu L; Zhu X; Ghiron C; Ermann M; Johnston D; Saluste CG
    J Med Chem; 2008 Mar; 51(6):1637-48. PubMed ID: 18278858
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Design and synthesis of Rho kinase inhibitors (II).
    Iwakubo M; Takami A; Okada Y; Kawata T; Tagami Y; Ohashi H; Sato M; Sugiyama T; Fukushima K; Iijima H
    Bioorg Med Chem; 2007 Jan; 15(1):350-64. PubMed ID: 17046269
    [TBL] [Abstract][Full Text] [Related]  

  • 7. N-Hydroxy-1,2-disubstituted-1H-benzimidazol-5-yl acrylamides as novel histone deacetylase inhibitors: design, synthesis, SAR studies, and in vivo antitumor activity.
    Wang H; Yu N; Song H; Chen D; Zou Y; Deng W; Lye PL; Chang J; Ng M; Sun ET; Sangthongpitag K; Wang X; Wu X; Khng HH; Fang L; Goh SK; Ong WC; Bonday Z; Stünkel W; Poulsen A; Entzeroth M
    Bioorg Med Chem Lett; 2009 Mar; 19(5):1403-8. PubMed ID: 19181524
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Discovery of pyrimidine benzimidazoles as Src-family selective Lck inhibitors. Part II.
    Zhang G; Ren P; Gray NS; Sim T; Wang X; Liu Y; Che J; Dong W; Tian SS; Sandberg ML; Spalding TA; Romeo R; Iskandar M; Wang Z; Seidel HM; Karanewsky DS; He Y
    Bioorg Med Chem Lett; 2009 Dec; 19(23):6691-5. PubMed ID: 19854052
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Novel 1H-(benzimidazol-2-yl)-1H-pyridin-2-one inhibitors of insulin-like growth factor I (IGF-1R) kinase.
    Wittman MD; Balasubramanian B; Stoffan K; Velaparthi U; Liu P; Krishnanathan S; Carboni J; Li A; Greer A; Attar R; Gottardis M; Chang C; Jacobson B; Sun Y; Hansel S; Zoeckler M; Vyas DM
    Bioorg Med Chem Lett; 2007 Feb; 17(4):974-7. PubMed ID: 17187980
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Discovery of a (1H-benzoimidazol-2-yl)-1H-pyridin-2-one (BMS-536924) inhibitor of insulin-like growth factor I receptor kinase with in vivo antitumor activity.
    Wittman M; Carboni J; Attar R; Balasubramanian B; Balimane P; Brassil P; Beaulieu F; Chang C; Clarke W; Dell J; Eummer J; Frennesson D; Gottardis M; Greer A; Hansel S; Hurlburt W; Jacobson B; Krishnananthan S; Lee FY; Li A; Lin TA; Liu P; Ouellet C; Sang X; Saulnier MG; Stoffan K; Sun Y; Velaparthi U; Wong H; Yang Z; Zimmermann K; Zoeckler M; Vyas D
    J Med Chem; 2005 Sep; 48(18):5639-43. PubMed ID: 16134929
    [TBL] [Abstract][Full Text] [Related]  

  • 11. N-(4-(6,7-Disubstituted-quinolin-4-yloxy)-3-fluorophenyl)-2-oxo-3-phenylimidazolidine-1-carboxamides: a novel series of dual c-Met/VEGFR2 receptor tyrosine kinase inhibitors.
    Mannion M; Raeppel S; Claridge S; Zhou N; Saavedra O; Isakovic L; Zhan L; Gaudette F; Raeppel F; Déziel R; Beaulieu N; Nguyen H; Chute I; Beaulieu C; Dupont I; Robert MF; Lefebvre S; Dubay M; Rahil J; Wang J; Ste-Croix H; Robert Macleod A; Besterman JM; Vaisburg A
    Bioorg Med Chem Lett; 2009 Dec; 19(23):6552-6. PubMed ID: 19854051
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Naphthamides as novel and potent vascular endothelial growth factor receptor tyrosine kinase inhibitors: design, synthesis, and evaluation.
    Harmange JC; Weiss MM; Germain J; Polverino AJ; Borg G; Bready J; Chen D; Choquette D; Coxon A; DeMelfi T; DiPietro L; Doerr N; Estrada J; Flynn J; Graceffa RF; Harriman SP; Kaufman S; La DS; Long A; Martin MW; Neervannan S; Patel VF; Potashman M; Regal K; Roveto PM; Schrag ML; Starnes C; Tasker A; Teffera Y; Wang L; White RD; Whittington DA; Zanon R
    J Med Chem; 2008 Mar; 51(6):1649-67. PubMed ID: 18324761
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Discovery of indazoles as inhibitors of Tpl2 kinase.
    Hu Y; Cole D; Denny RA; Anderson DR; Ipek M; Ni Y; Wang X; Thaisrivongs S; Chamberlain T; Hall JP; Liu J; Luong M; Lin LL; Telliez JB; Gopalsamy A
    Bioorg Med Chem Lett; 2011 Aug; 21(16):4758-61. PubMed ID: 21742493
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Optimization of a pyrazole hit from FBDD into a novel series of indazoles as ketohexokinase inhibitors.
    Zhang X; Song F; Kuo GH; Xiang A; Gibbs AC; Abad MC; Sun W; Kuo LC; Sui Z
    Bioorg Med Chem Lett; 2011 Aug; 21(16):4762-7. PubMed ID: 21767952
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Structure-driven HtL: design and synthesis of novel aminoindazole inhibitors of c-Jun N-terminal kinase activity.
    Stocks MJ; Barber S; Ford R; Leroux F; St-Gallay S; Teague S; Xue Y
    Bioorg Med Chem Lett; 2005 Jul; 15(14):3459-62. PubMed ID: 15950471
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discovery of novel 4-amino-6-arylaminopyrimidine-5-carbaldehyde oximes as dual inhibitors of EGFR and ErbB-2 protein tyrosine kinases.
    Xu G; Searle LL; Hughes TV; Beck AK; Connolly PJ; Abad MC; Neeper MP; Struble GT; Springer BA; Emanuel SL; Gruninger RH; Pandey N; Adams M; Moreno-Mazza S; Fuentes-Pesquera AR; Middleton SA; Greenberger LM
    Bioorg Med Chem Lett; 2008 Jun; 18(12):3495-9. PubMed ID: 18508264
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Design, synthesis, and evaluation of orally active benzimidazoles and benzoxazoles as vascular endothelial growth factor-2 receptor tyrosine kinase inhibitors.
    Potashman MH; Bready J; Coxon A; DeMelfi TM; DiPietro L; Doerr N; Elbaum D; Estrada J; Gallant P; Germain J; Gu Y; Harmange JC; Kaufman SA; Kendall R; Kim JL; Kumar GN; Long AM; Neervannan S; Patel VF; Polverino A; Rose P; Plas Sv; Whittington D; Zanon R; Zhao H
    J Med Chem; 2007 Sep; 50(18):4351-73. PubMed ID: 17696416
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synthesis and antiproliferative activity of 3-amino-N-phenyl-1H-indazole-1-carboxamides.
    Raffa D; Maggio B; Cascioferro S; Raimondi MV; Schillaci D; Gallo G; Daidone G; Plescia S; Meneghetti F; Bombieri G; Di Cristina A; Pipitone RM; Grimaudo S; Tolomeo M
    Eur J Med Chem; 2009 Jan; 44(1):165-78. PubMed ID: 18485541
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel C-3 N-urea, amide, and carbamate dihydroindazolo[5,4-a]pyrrolo[3,4-c]carbazole analogs as potent TIE-2 and VEGF-R2 dual inhibitors.
    Becknell NC; Zulli AL; Angeles TS; Yang S; Albom MS; Aimone LD; Robinson C; Chang H; Hudkins RL
    Bioorg Med Chem Lett; 2006 Oct; 16(20):5368-72. PubMed ID: 16890434
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Structure-based design, synthesis, and antimicrobial activity of indazole-derived SAH/MTA nucleosidase inhibitors.
    Li X; Chu S; Feher VA; Khalili M; Nie Z; Margosiak S; Nikulin V; Levin J; Sprankle KG; Tedder ME; Almassy R; Appelt K; Yager KM
    J Med Chem; 2003 Dec; 46(26):5663-73. PubMed ID: 14667220
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.